drugset / Trial / NCT02538627
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-10-05
- Completion
- 2016-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MM-151 | Unknown | — | — |
| Subject | Seribantumab | Monoclonal antibody | — | — |
| Subject | Trametinib | Small molecule | — | — |
| Subject | istiratumab | Monoclonal antibody | — | — |